A new study in *Nature Communications* reveals that asymptomatic transmission of mpox is possible, challenging prior assumptions and reshaping public health strategies. The research, conducted in 2026, highlights the need for expanded vaccination and testing protocols.
The study, led by Dr. Joseph A. Lewnard and colleagues, analyzed 8,000 men who have sex with men (MSM) in Los Angeles, finding 1% tested positive for mpox without symptoms. This suggests underdiagnosis and underscores the role of asymptomatic carriers in sustaining outbreaks. The findings align with global trends where mpox transmission disproportionately affects MSM and transgender communities, particularly during large gatherings or sexual encounters.
In Plain English: The Clinical Takeaway
- Up to 1 in 33 mpox infections may go undiagnosed due to asymptomatic cases.
- The JYNNEOS vaccine reduces infection risk by 50%, but vaccination rates have declined since the 2022 outbreak.
- Asymptomatic transmission complicates contact tracing, requiring broader testing and public awareness.
The study’s methodology involved molecular testing of routine STI samples, revealing genetic patterns confirming non-symptomatic spread. This aligns with earlier observations by the World Health Organization (WHO) that mpox transmission often occurs through close physical contact, not just visible sores. Dr. Maria Van Kerkhove, WHO’s Technical Lead for Mpox, noted, “These findings reinforce the importance of universal precautions, even in the absence of visible symptoms.”
Deep Dive: Epidemiology, Funding and Global Impact
The research, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation, utilized a prospective cohort design. While not a randomized controlled trial, its large sample size (N=7,982) and integration of genomic sequencing enhance credibility. The study’s authors emphasize that asymptomatic cases may account for 20-30% of total transmissions, based on modeling from the 2022 outbreak.
| Parameter | 2022 Outbreak | 2026 Study |
|---|---|---|
| Asymptomatic Cases | Estimated 10-15% | 1% detected; likely higher |
| Vaccine Efficacy (JYNNEOS) | 50-70% (phase III trials) | 50% (2026 study) |
| Diagnosis Rate | ~30% | ~97% (study cohort) |
Regional healthcare systems face unique challenges. In the U.S., the FDA’s Emergency Use Authorization (EUA) for JYNNEOS in 2022 prioritized high-risk groups, but supply shortages and vaccine hesitancy limited coverage. The NHS in the UK adopted similar strategies, while the European Medicines Agency (EMA) emphasized post-vaccination surveillance. Dr. Sarah M. Bauman, an epidemiologist at the CDC, stated, “Asymptomatic spread necessitates a shift from symptom-based to contact-based public health interventions.”
Contraindications & When to Consult a Doctor
Individuals with severe allergies to vaccine components (e.g., neomycin) or immunocompromised states (e.g., HIV with low CD4 count) should avoid JYNNEOS. Those experiencing fever, malaise, or skin lesions after potential exposure should seek medical evaluation within 72 hours. High-risk groups—such as MSM, transgender individuals, and those with HIV—require routine screening, even without symptoms.
The study’s implications are profound. Public health campaigns must now prioritize asymptomatic transmission in messaging, urging safer sex practices and vaccination. As Dr. Lewnard noted, “Unvaccinated individuals face heightened risks, and our data suggest these risks are larger than previously thought.” Future efforts will focus on improving vaccine accessibility, particularly in low-resource settings where mpox remains endemic.
